Prognostic Significance Of Platelet-To-Lymphocyte Ratio (PLR) And Mean Platelet Volume (MPV) During Etoposide-Based First-Line Treatment In Small Cell Lung Cancer Patients

References

• Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: small cell lung cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16(10):1171–1182. doi:10.6004/jnccn.2018.007930323087
   PubMed Web of Science ®Google Scholar
• Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev. 2018;281(1):57–61. doi:10.1111/imr.1261429247996
   PubMed Web of Science ®Google Scholar
• Loffek S. Transforming of the tumor microenvironment: implications for TGF-β inhibition in the context of immune-checkpoint therapy. J Oncol. 2018;2018:9732939. doi:10.1155/2018/973293930631358
   PubMed Web of Science ®Google Scholar
• Varga G, Foell D. Anti-inflammatory monocytes-interplay of innate and adaptive immunity. Mol Cell Pediatr. 2018;5(1):5. doi:10.1186/s40348-018-0083-429616417
   PubMedGoogle Scholar
• Magdy M, Hussein T, Ezzat A, Gaballah A. Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic marker in gastric cancer. J Gastrointest Cancer. 2018;1–6. doi:10.1007/s12029-018-0144-x29110227
   PubMed Web of Science ®Google Scholar
• Vallard A, Garcia MA, Diao P, et al. Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarker. Oncotarget. 2018;9(32):22368–22382. doi:10.18632/oncotarget.2502329854285
   PubMedGoogle Scholar
• Hong YF, Chen ZH, Wei L, et al. Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-associated advanced hepatocellular carcinoma. Oncol Lett. 2017;14(2):2089–2096. doi:10.3892/ol.2017.642028789436
   PubMed Web of Science ®Google Scholar
• Yang J, Xu H, Guo X, et al. Pretreatment inflammatory indexes as prognostic predictors for survival in colorectal cancer patients receiving neoadjuvant chemoradiotherapy. Sci Rep. 2018;8(1):3044. doi:10.1038/s41598-018-21093-729445100
   PubMed Web of Science ®Google Scholar
• Yang J, Guo X, Wang M, Ma X, Ye X, Lin P. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS. Sci Rep. 2017;7(1):17166. doi:10.1038/s41598-017-17130-629215037
   PubMedGoogle Scholar
• Aguiar-Bujanda D, Dueñas-Comino A, Saura-Grau S, et al. Neutrophil to lymphocyte ratio as a prognostic factor in European patients with epidermal growth factor receptor-mutant non-small cell lung cancer treated with tyrosine kinase inhibitors. Oncol Res Ther. 2018;41(12):755–761. doi:10.1159/000492344
   Google Scholar
• Suh KJ, Kim SH, Kim YJ, et al. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother. 2018;67(3):459–470. doi:10.1007/s00262-017-2092-x29204702
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang H, Li Y, Wang D, Ma Y, Chen Q. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. Clin Chim Acta. 2018;484:272–277. doi:10.1016/j.cca.2018.05.05929860033
   PubMed Web of Science ®Google Scholar
• Luo H, Ge H, Cui Y, et al. Systemic inflammation biomarkers predict survival in patients of early stage non-small cell lung cancer treated with stereotactic ablative radiotherapy – a single center experience. J Cancer. 2018;9(1):182–188. doi:10.7150/jca.2170329290784
   PubMed Web of Science ®Google Scholar
• Song X, Chen D, Yuan M, Wang H, Wang Z. Total lymphocyte count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer with chemoradiotherapy. Cancer Manag Res. 2018;10:6677–6683. doi:10.2147/CMAR.S18857830584362
   PubMed Web of Science ®Google Scholar
• Guo F, Zhu X, Qin X. Platelet distribution width in hepatocellular carcinoma. Med Sci Monit. 2018;24:2518–2523.29689031
   PubMed Web of Science ®Google Scholar
• Cui MM, Li N, Liu X, et al. Platelet distribution width correlates with prognosis of non-small cell lung cancer. Sci Rep. 2017;7(1):3456. doi:10.1038/s41598-017-03772-z28615714
   PubMed Web of Science ®Google Scholar
• Lee JH, Park M, Han S, et al. An increase in mean platelet volume during admission can predict the prognoses of patients with pneumonia in the intensive care unit: a retrospective study. PLoS One. 2018;13(12):e0208715. doi:10.1371/journal.pone.020871530533065
   PubMed Web of Science ®Google Scholar
• Bernhardt D, Aufderstrasse S, König L, et al. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Manag Res. 2018;10:6563–6569. doi:10.2147/CMAR.S18099030555261
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang L, Zhao W, et al. Risk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiation. Strahlenther Onkol. 2018;194(12):1152–1162. doi:10.1007/s00066-018-1362-730218136
   PubMed Web of Science ®Google Scholar
• Suzuki R, Lin SH, Wei X, et al. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018;126(3):499–505. doi:10.1016/j.radonc.2017.12.03029398150
   PubMed Web of Science ®Google Scholar
• Liu D, Huang Y, Li L, Song J, Zhang L, Li W. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer. 2017;17(1):882. doi:10.1186/s12885-017-3893-129268698
   PubMed Web of Science ®Google Scholar
• Kasmann L, Bolm L, Schild SE, Janssen S, Rades D. Neutrophil-to-lymphocyte ratio predicts outcome in limited disease small-cell lung cancer. Lung. 2017;195(2):217–224. doi:10.1007/s00408-017-9976-628154994
   PubMed Web of Science ®Google Scholar
• Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014;111(3):452–460. doi:10.1038/bjc.2014.31724921916
   PubMed Web of Science ®Google Scholar
• Shi L, Li Y, Yu T, et al. Predictable resistance and overall survival of gemcitabine/cisplatin by platelet activation index in non-small cell lung cancer. Med Sci Monit. 2018;24:8655–8668. doi:10.12659/MSM.91112530498189
   PubMed Web of Science ®Google Scholar
• Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer. 2014;83(1):97–101. doi:10.1016/j.lungcan.2013.08.02024189108
   PubMed Web of Science ®Google Scholar
• Omar M, Tanriverdi O, Cokmert S, et al. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J. 2018;12(3):922–929. doi:10.1111/crj.1260528026133
   PubMed Web of Science ®Google Scholar
• Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic significance of total lymphocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in limited-stage small-cell lung cancer. Clin Lung Cancer. 2019;20(2):117–123. doi:10.1016/j.cllc.2018.11.01330611672
   PubMed Web of Science ®Google Scholar